TYMS and frontotemporal dementia: Increase in TS protein level, a pharmacodynamic marker of inhibition of TS activity by fluoropyrimidine derivatives (Chu et al., 1991), was observed with a similar extent in cells treated with both FTD alone and FTD/panitumumab combination.